论文部分内容阅读
目的 :探讨曲美他嗪联合低分子肝素 (LMWH)对老年冠心病心绞痛的临床疗效。方法 :6 8例老年冠心病心绞痛患者随机分成联合治疗组和常规治疗组 ,在常规抗心绞痛疗法基础上 ,联合治疗组加用曲美他嗪和LMWH ,其中曲美他嗪 6 0～ 12 0mg/d ,分 3次口服 ,疗程 30d ;LMWH 0 .3～ 0 .6ml (2 85 0～ 5 70 0IU) ,每日 1～ 2次皮下注射 ,连续 7～ 15d。观察两组临床疗效及随访至治疗后 30d的心脏事件。结果 :联合治疗组总有效率为94 .12 % ,常规治疗组总有效率为 70 .5 9% ,两组疗效比较差异有显著性意义 (P <0 .0 5 )。结论 :老年冠心病心绞痛患者常并发其他心脑血管病、糖尿病等疾患 ,对这类患者联用曲美他嗪和LMWH可获满意疗效
Objective: To investigate the clinical efficacy of trimetazidine combined with low molecular weight heparin (LMWH) in elderly patients with angina pectoris. Methods: Sixty-eight elderly patients with angina pectoris were randomly divided into combined treatment group and conventional treatment group. On the basis of conventional anti-anginal therapy, trimetazidine and LMWH were added to the combined treatment group, with trimetazidine 60 ~ 120mg / d, 3 times orally, the course of treatment 30d; LMWH 0 .3 ~ 0. 6ml (2 85 0 ~ 5 70 0IU), 1 or 2 times a day subcutaneous injection for 7 ~ 15d. The clinical efficacy and follow-up of the two groups were observed 30 days after treatment of cardiac events. Results: The total effective rate was 94.12% in the combined treatment group and 70.59% in the conventional treatment group. There was significant difference between the two groups (P <0.05). Conclusion: Elderly patients with coronary heart disease often complicated by cardiovascular and cerebrovascular diseases, diabetes and other diseases, such patients combined trimetazidine and LMWH can be satisfied with the desired effect